Literature DB >> 25862986

It Is Time to Treat to Trough: Staying Ahead of the Curve in Biologic Testing.

Byron P Vaughn1, Adam S Cheifetz2.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25862986     DOI： 10.1016/j.cgh.2015.03.031

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


× No keyword cloud information.
  3 in total

1.  Higher Adalimumab Drug Levels Are Associated with Mucosal Healing in Patients with Crohn's Disease.

Authors:  Konstantinos Papamichael; Adam S Cheifetz
Journal:  J Crohns Colitis       Date:  2016-02-13       Impact factor: 9.071

2.  The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease.

Authors:  A N Ananthakrishnan; A Sakuraba; E L Barnes; J Pekow; L Raffals; M D Long; R S Sandler
Journal:  Aliment Pharmacol Ther       Date:  2017-05-03       Impact factor: 8.171

3.  Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients.

Authors:  So Yoon Choi; Young Ok Choi; Yon Ho Choe; Ben Kang
Journal:  J Korean Med Sci       Date:  2020-04-27       Impact factor: 2.153
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.